Drug Prices

Drug Prices

NEW STUDY: 340B Providers Reap Big Profits, Should Be Reformed to Ensure At-Risk Patients Receive Affordable Care

SACRAMENTO – The broken 340B program, designed to provide affordable care for at-risk patients, creates massive profits for providers without necessarily improving patient health outcomes and should be reformed, finds a new issue brief released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute. …

Drug Innovation

NEW BRIEF: Promoting Transparency and Competition in the Drug Market

DOWNLOAD THE BRIEF   BY WAYNE WINEGARDEN AND CELINE BOOKIN In addition to the reforms to the health insurance system, which will help address the problems of drug affordability, reforms tailored to the pharmaceutical sector are necessary. These reforms should eliminate drug supply chain inefficiencies and include:   fostering a …

Drug Prices

Sally Pipes Discusses Prescription Drugs and Inflation Reduction Act on Eric Bolling: The Balance

Watch PRI President, CEO, and Thomas W. Smith Fellow in Health Care Policy discuss prescription drug costs and the so-called Inflation Reduction Act on “Eric Bolling: The Balance” on Newsmax TV. 

Commentary

Drug price controls would limit new medicines

The Democrats’ budget reconciliation bill is winding its way through the Senate. Last week, Republican and Democratic senators met with the chamber’s parliamentarian to discuss whether the bill’s proposal for Medicare to negotiate the price of prescription drugs with manufacturers has a direct impact on government spending or tax revenue, as reconciliation …

Drug Prices

NEW STUDY: Creating Two-Part Drug Pricing System Would Ensure Prices More Accurately Reflect How Patients

Establishing a two-part drug pricing system quantifying separate values for a drug’s innovation and production would create an efficient market and a more accurate reflection of how patients value a drug compared to those produced by centralized organizations, argues a new report released today by the Center for Medical Economics …

Drug Prices

NEW STUDY: 340B Providers Reap Big Profits, Should Be Reformed to Ensure At-Risk Patients Receive Affordable Care

SACRAMENTO – The broken 340B program, designed to provide affordable care for at-risk patients, creates massive profits for providers without necessarily improving patient health outcomes and should be reformed, finds a new issue brief released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute. …

Drug Innovation

NEW BRIEF: Promoting Transparency and Competition in the Drug Market

DOWNLOAD THE BRIEF   BY WAYNE WINEGARDEN AND CELINE BOOKIN In addition to the reforms to the health insurance system, which will help address the problems of drug affordability, reforms tailored to the pharmaceutical sector are necessary. These reforms should eliminate drug supply chain inefficiencies and include:   fostering a …

Drug Prices

Sally Pipes Discusses Prescription Drugs and Inflation Reduction Act on Eric Bolling: The Balance

Watch PRI President, CEO, and Thomas W. Smith Fellow in Health Care Policy discuss prescription drug costs and the so-called Inflation Reduction Act on “Eric Bolling: The Balance” on Newsmax TV. 

Commentary

Drug price controls would limit new medicines

The Democrats’ budget reconciliation bill is winding its way through the Senate. Last week, Republican and Democratic senators met with the chamber’s parliamentarian to discuss whether the bill’s proposal for Medicare to negotiate the price of prescription drugs with manufacturers has a direct impact on government spending or tax revenue, as reconciliation …

Drug Prices

NEW STUDY: Creating Two-Part Drug Pricing System Would Ensure Prices More Accurately Reflect How Patients

Establishing a two-part drug pricing system quantifying separate values for a drug’s innovation and production would create an efficient market and a more accurate reflection of how patients value a drug compared to those produced by centralized organizations, argues a new report released today by the Center for Medical Economics …

Scroll to Top